Synergistic pharmaceutical compositions

a technology of pharmaceutical compositions and compositions, applied in the field of synergistic pharmaceutical compositions, can solve the problems of affecting much of the skin, excessive growth, and no one knows what causes abnormal cell proliferation

Inactive Publication Date: 2000-03-07
PSORIAL
View PDF14 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

.Iadd.As will be described and exemplified hereinafter with regard to Example 2, it has now been surprisingly found and proven that a combination of as little as 0.01% halcinonide and 0.01% triamcinolone acetonide is more effective in the treatment of severe psoriasis than 0.3% halcinonide or 0.3% triamcinolone acetonide when administered separately. While said combination does not remove all the spots associated with severe psoriasis, it is effective for treating mild psoriasis, eczema and dermatitis as well as other dermatological conditions and even lower dosages of the newly discovered synergistic combination of the present invention should be effective for treating milder dermatological conditions involving dry and / or itchy skin.

Problems solved by technology

These plaques are the result of an excessively rapid growth and shedding of epidermal (skin) cells.
No one knows what causes this abnormal cell proliferation.
Occasionally the disease may be very severe, affecting much of the skin and causing considerable disability in the patient.
There is no known cure and treatment is palliative with lotions or ointments.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synergistic pharmaceutical compositions
  • Synergistic pharmaceutical compositions
  • Synergistic pharmaceutical compositions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

.].

.[.Two compositions according to the present invention were prepared in the following manner:

.[.Preparation of the Base.].

.[.Vaseline (70%) was mixed with lanolin (20%) and lanet wax (10%) was added while heating at a temperature not exceeding 70.degree. C. and mixing constantly in order to maximize the homogenicity of the base, 30% water was added at 70.degree. C..].

.[.Active Ingredients.].

.[.1 1a) Per 100 g ointment--200 mg haleinonide 100 mg triamcinolene.].

.[.1 1b) Forte. per 100 g ointment--300 mg haleinonide 100 mg triamcinolone.].

.[.The above amounts of active ingredients were respectively mixed together with a mortar and pestle with the held of a drop of parafin. While mixing constantly the base was added drop by drop at first, then more rapidly, until a total amount of 100 gm was obtained..].

.[.COMPARATIVE EXAMPLE 2.].

.[.1 a) A comparative composition was prepared as in example 1, however having only 0.1% halcinonide and 0.1% triamcinolone actamide in the final compositi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

[A pharmaceutical composition comprises a synergistic combination of about 0.01-0.15% by wt. triamcinolone acetonide and about 0.04-0.3% by wt. halcinonide as active ingredients, in combination with a pharmaceutically acceptable carrier.]A pharmaceutical composition comprises a synergistic combination of at least about 0.01% by wt. triamcinolone acetonide and at least about 0.01% by wt. halcinonide as active ingredients therein, in combination with a pharmaceutically acceptable carrier.

Description

The present invention relates to a pharmaceutical composition for treating psoriasis. More particularly, the present invention relates to a composition containing 16.alpha., 17.alpha.-substituted methylenedioxy steroids as active ingredients therein..]..[.It has been known for over 25 years that 11-substituted 16.alpha.,17.alpha.-substituted methylene dioxysteroids of the pregnane series, as described. e.g.. in U.S. Pat. No. 2,990,401, have high anti-inflammatory activity and can be used topically in the treatment of burns, rheumatoid arthritis, allergies, psoriasis and other skin disorders..]..[.Among the compounds taught in said patent, it is now well-known that triamcinolone acetonide, which is 9.alpha.-fluoro-11.beta.-21-dihydroxy-16.alpha.,17.alpha.-isopropylidenedi oxy-1,4pregnadiene-3,20-dione, has proved particularly useful in the treatment of dermatological conditions. The compound has been proved to have marked efficacy in the treatment of dermatosis, eczema. neurodermitis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K31/57
CPCA61K31/57A61K2300/00
Inventor CHRIKI, GEORGES
Owner PSORIAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap